Pulmonary fibrosis in dyskeratosis congenita with TINF2 gene mutation Source: Eur Respir J 2013; 42: 1757-1759 Year: 2013
Progressive phenotype in primary Sjögren's syndrome-associated interstitial lung diseases: Prognostic significance Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020
Prognostic and clinical value of cluster analysis of idiopathic pleuroparenchymal fibroelastosis phenotypes Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019
Pulmonary function test in patients with myelodysplastic syndrome Source: Eur Respir J 2002; 20: Suppl. 38, 445s Year: 2002
Lung abnormalities in marfan syndrome: a pathogenetic model of early-onset emphysema? Source: Annual Congress 2009 - Respiratory physiology Year: 2009
Pulmonary function tests in multisystem disorders: prejudices and pitfalls Source: Eur Respir Monogr 2019; 86: 14-26 Year: 2019
Pulmonary function tests in childhood scleroderma Source: Eur Respir J 2006; 28: Suppl. 50, 307s Year: 2006
Idiopathic pulmonary fibrosis phenotypes: Identification of new clinico-pathological stigmata Source: Annual Congress 2010 - Clinical issues in idiopathic pulmonary fibrosis Year: 2010
Idiopathic pulmonary fibrosis: Clinical, radiological and functional significance of biomarkers of proliferation Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease Year: 2012
Prognostic significance of clinical and morphological features in idiopathic interstitial pneumonias Source: Eur Respir J 2002; 20: Suppl. 38, 61s Year: 2002
Pulmonary function test abnormalities in Parkinson‘s disease Source: Eur Respir J 2007; 30: Suppl. 51, 340s Year: 2007
Prognostic value of modified classification based on lung function tests in idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2006; 28: Suppl. 50, 827s Year: 2006
A rare diagnosis: Hermansky-Pudlak syndrome in a patient with pulmonary fibrosis, oculocutaneous albinism and thrombocytopathy Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment Year: 2019
Prolidase deficiency: a new genetic cause of combined pulmonary fibrosis and emphysema syndrome in the adult Source: Eur Respir J, 55 (4) 1901952; 10.1183/13993003.01952-2019 Year: 2020
Lymphoproliferative lung disorders: clinicopathological aspects Source: Eur Respir Rev 2013; 22: 427-436 Year: 2013
Pathophysiology of pulmonary function anomalies in COVID-19 survivors Source: Breathe, 17 (3) 210065; 10.1183/20734735.0065-2021 Year: 2021
Pulmonary eosinophilic syndromes characterization. The role of peripheral eosinophilia as a marker of clinical evolution Source: Annual Congress 2012 - Diffuse parenchymal lung disease II Year: 2012
Pulmonary features of autosomal dominant hyper-IgE syndrome [AD HIES] Source: Annual Congress 2011 - New insights in management of interstitial and vascular lung diseases Year: 2011
Pulmonary disease in primary Sjögren´s syndrome: symptoms, pulmonary function tests and HRCT Source: Eur Respir J 2004; 24: Suppl. 48, 487s Year: 2004
Prognostic significance of pathologically proven chronic fibrosing interstitial lung diseases with a progressive phenotype (PF-ILDs): single center retrospective cohort Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020